Influenza A causes seasonal epidemics, as well as sporadic, large-scale pandemics, in human hosts, with associated high levels of mortality and morbidity \[[@CIT0001]\]. In immunocompromised and immunosuppressed children, the risk of mortality is even higher \[[@CIT0002]\]. These patients also tend to shed the virus over a prolonged period, leading to higher chances of transmission \[[@CIT0003], [@CIT0004]\]. For this reason, it is important to monitor transmission in a hospital setting housing both immunocompromised and immunosuppressed patients.

Haemagglutinin (HA) and neuraminidase (NA) gene sequencing have been routinely used in hospitals to confirm influenza outbreak clusters among patients \[[@CIT0005]\]. Gene sequencing also provides information on genotypes, subtypes, and drug resistance in a hospital setting \[[@CIT0003]\]. In recent years, whole-genome sequencing (WGS) has been widely used to conduct outbreak investigations of a wide range of infectious pathogens \[[@CIT0008]\], with a few studies focusing on the epidemiology of the influenza virus \[[@CIT0012], [@CIT0013]\]. A recent study concluded that, in the hospital setting, WGS did not provide any additional information on influenza outbreaks and transmission chains, compared to HA/NA gene sequencing alone \[[@CIT0014]\]. This conclusion is attractive, as sequencing of the influenza HA and NA genes is routinely used for genotyping strains \[[@CIT0003], [@CIT0004]\]. Here, we tested the value of WGS as a clinical tool for the identification of potential nosocomial transmission, and we discuss whether it could be useful in real time.

METHODS {#s1}
=======

Residual nasopharyngeal aspirate samples were collected from all patients who tested positive for influenza A (H1N1) at Great Ormond Street Hospital (GOSH) during January to March 2016. The study was approved under the University College of London Pathogen BioBank National Research Ethics Committee London--Fulham (Research Ethics Committee number 17/LO/1530)

Overall, 80 samples were sequenced at multiple time points from 38 individuals. Samples were sequenced using the Agilent SureSelect^XT^ (SSXT) targeted enrichment method, as previously described \[[@CIT0015], [@CIT0016]\]. Custom 120-mer RNA baits were designed using a comprehensive set of influenza A sequences. Bait sets were validated using clinical samples from multiple hospitals in the United Kingdom \[[@CIT0017], [@CIT0018]\]. Sequencing libraries were prepared using the 200ng input SureSelect XT protocol and sequenced on an Illumina MiSeq sequencer. Sequences were assembled using a reference-based pipeline in CLC Genomics Workbench version 8.03, and consensus sequences were extracted with a minimum of 10X coverage. Alignments were made using MAFFT 7.212 \[[@CIT0019]\]. Maximum likelihood trees were computed for the sequenced strains, along with other database H1N1 strains, in PhyML 3.1 \[[@CIT0020]\] with 500 bootstrap replicates and were visualized using FigTree 1.4.2 (<http://tree.bio.ed.ac.uk/software/figtree/>). Pairwise single-nucleotide variations were computed using the ape package (dist.dna) in R. Clinical data were obtained from a review of the patient records. The transmission network was constructed using PopART \[[@CIT0021]\].

RESULTS {#s2}
=======

The patient population comprised 38 children, 32 from GOSH and 6 as inpatients in other hospitals, with influenza A detected by polymerase chain reaction of nasopharyngeal aspirates ([Table 1](#T1){ref-type="table"}). Complete sequence data were obtained from 36 patients, while 2 patients failed sequencing. Routine epidemiology was obtained from infection prevention and control (IPC) team activity: 9 of the patients developed symptoms more than 48 hours after admission and were thus deemed to have health-care--associated infections. There were 3 children who were linked by IPC data on 1 ward (cases 25, 26, and 27; [Table 1](#T1){ref-type="table"}) and considered to be an outbreak. There were 2 children who had recently been on another ward (cases 27 and 35) and were considered as possibly linked by IPC methods. In addition, there were 11 patients (Patients 37, 39, 42, 43, 58, 59, 63, 70, 75, 76, and 77; [Table 1](#T1){ref-type="table"}) linked to the haematology/oncology/immunology/bone marrow transplant services, who shared some patient services and were suspected to have cross-infections, but a connection between those patients had not been conclusively demonstrated by conventional IPC.

###### 

Clinical Details for Patients Sequenced as Part of the Study

  Patient No   Ward    Service         Date of Admission or OP Visit   Specimen Collection Date   Location When Tested   Status When Sampled   Days IP Before Onset   Prior GOSH Contact if Not HCAI   Period Since Any Contact With the Hospital if Not HCAI   Linked and Possibly Linked Patient (Pairwise Distance) With All GOSH Strains   Comments
  ------------ ------- --------------- ------------------------------- -------------------------- ---------------------- --------------------- ---------------------- -------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------
  25^a^        R       Metabolic       26/08/2015                      25/01/2016                 IP                     HCAI                  152                    NA                               NA                                                       26 (2), 27 (1)                                                                 Index case. Infected 26 and 27 on the same ward
  26^a^        R       Endocrine       04/01/2016                      26/01/2016                 IP                     HCAI                  22                     NA                               NA                                                       25 (2), 27 (1)                                                                 Same ward as 25 and 27
  27^a^        R       Endocrine       04/01/2016                      27/01/2016                 IP                     HCAI                  23                     NA                               NA                                                       25 (1), 26 (1)                                                                 Same ward as 25 and 26
  53^b,c,d^    B       IPP             14/01/2016                      15/01/2016                 IP                     POA                   NA                     Y                                2 days                                                   54 (1), 45 (7), 49 (8), 81 (8), 36 (9), 70 (10), 37 (11)                       OPD 12/01/2016
  54^b,c,e^    B       IPP             07/01/2016                      15/01/2016                 IP                     HCAI                  8                      NA                               NA                                                       53 (1), 45 (6), 49 (7), 81 (7), 36 (8), 70 (9)                                 Mother unwell
  36^b,d^      PI      ICU             31/01/2016                      01/02/2016                 IP                     POA                   NA                     None                             NA                                                       37 (8), 54 (8), 53 (9), 70 (9), 45 (10), 49 (11)                               New patient
  37^b,d^      EL      Haem/onc        05/02/2016                      05/02/2016                 IP                     POA                   NA                     Y                                7 days                                                   36 (8), 54 (10)                                                                OPD 15/01/16
  45^b^        EXT     External        None                            11/02/2016                 Ext                    EXT                   NA                     Y                                5 months                                                 54 (6), 53 (7), 49 (9), 36 (10), 70 (11)                                       OPD 15/09/2015 referred sample
  49^b,c,e^    PP      IPP/ENT         11/02/2016                      22/02/2016                 IP                     HCAI                  11                     NA                               NA                                                       54 (7), 53 (8), 45 (9), 36 (11)                                                
  70^b^        HAOPD   Haem/onc        11/03/2016                      11/03/2016                 OP                     POPD                  NA                     None                             NA                                                       36 (9), 54 (9), 53 (10), 37 (11), 45 (11)                                      OPD and not admitted
  81^b,e^      SQUIR   Surgical        15/09/2015                      25/03/2016                 IP                     HCAI                  192                    NA                               NA                                                       54 (7), 53 (8)                                                                 
  38^f^        PI      ICU             05/02/2016                      05/02/2016                 IP                     POA                   NA                     Y                                2 months                                                 40 (7), 35 (23)                                                                OPD 10/12/2015
  40^f^        EXT     External        None                            28/01/2016                 Ext                    EXT                   NA                     Y                                1.5 months                                               38 (7), 35 (20)                                                                OPD 18/12/2015 referred sample
  43^g^        EL      Haem/onc        21/01/2016                      09/02/2016                 IP                     HCAI                  19                     None                             NA                                                       36 (21), 54 (21)                                                               New patient
  58^g^        G       Haem/onc        24/01/2016                      26/01/2016                 IP                     POA                   NA                     Y                                3 days                                                   36 (21), 54 (21)                                                               OPD 23/01/16. OPD 21/01/2016.
  39^g^        HAOPD   Haem/onc        29/01/2016                      29/01/2016                 OP                     POA                   NA                     Y                                2.5 months                                               35 (41), 36 (42), 54 (42)                                                      HAOPD 6/11/2015
  59^g^        EL      Haem/onc        25/02/2016                      25/02/2016                 IP                     POA                   NA                     Y                                3 days                                                   35(90), 36 (90), 54 (90)                                                       IP GOSH 16/2--22/2/16 parents were symptomatic.
  63^g^        HAOPD   Haem/onc        02/03/2016                      02/03/2016                 OP                     POA                   NA                     Y                                20 days                                                  35 (157), 42 (158)                                                             HAOPD 12/02/2016
  75^g^        HAOPD   Haem/onc        16/03/2016                      16/03/2016                 OP                     POA                   NA                     Y                                29 days                                                  36(25), 54 (25)                                                                HAOPD 15/02/2016
  76^g^        HAOPD   Haem/onc        16/03/2016                      16/03/2016                 OP                     POA                   NA                     Y                                20 days                                                  36 20), 54 (20)                                                                HAOPD 24/02/2016,
  77^g^        HAOPD   Haem/onc        16/03/2016                      16/03/2016                 OP                     POA                   NA                     Y                                19 days                                                  36 25), 54 (25)                                                                IP 23/02/2016 25/02/2016
  35           EA      Renal           01/02/2016                      01/02/2016                 IP                     POA                   NA                     Y                                2 days                                                   27 (13), 25 (14), 26 (14)                                                      OPD 20 and 21/01/2016; admission 28/01-30/01/2016
  62^f^        BU      IPP             01/03/2016                      02/03/2016                 IP                     POA                   NA                     Y                                27 days                                                  53 (13), 54 (12)                                                               IP 12--14/1/2016 OPD 2/02/2016
  69           BA      Resp            06/03/2016                      10/03/2016                 IP                     HCAI                  4                      Y                                25 days                                                  36 (12), 37 (14), 54 (14)                                                      OPD 9/2/2016;
  47^f^        PI      ICU             15/02/2016                      16/02/2016                 IP                     POA                   NA                     Y                                2 months                                                 36 (12), 54 (12)                                                               IP GOSH 22/11--8/12/2015;
  60^f^        PI      ICU             28/02/2016                      28/02/2016                 IP                     POA                   NA                     None                             NA                                                       36 (12), 54 (12)                                                               New patient
  79           P       Rheum           17/03/2016                      18/03/2016                 IP                     POA                   NA                     Y                                13 days                                                  36 (13), 37 (15), 54 (15)                                                      OPD 4/3/2016
  42           EXT     External        None                            01/02/2016                 Ext                    EXT                   NA                     Y                                2 months                                                 36 (15), 54 (15)                                                               IP GOSH 21/10/2015; referred sample
  73           EXT     External        None                            12/03/2016                 Ext                    EXT                   NA                     None                             NA                                                       36 (17), 54 (17)                                                               No GOSH contact; referred sample
  74           K       Neurosurgical   14/03/2016                      16/03/2016                 IP                     POA                   NA                     Y                                2 months                                                 36 (18), 54 (18)                                                               OPD 19/01/2016,
  51           PI      ICU             11/01/2016                      12/01/2016                 IP                     POA                   NA                     Y                                8.5 months                                               36 (22),53 (22), 54 (22)                                                       OPD 27/04/2015
  55^b^        SQ      Surgical        22/12/2015                      18/01/2016                 IP                     HCAI                  27                     NA                               NA                                                       36 (23), 54 (23)                                                               Father had a respiratory infection
  34           EA      Renal           31/01/2016                      31/01/2016                 IP                     POA                   NA                     Y                                4 years                                                  36 (23), 54 (23)                                                               IP and OPD 2012.
  61           EXT     External        None                            01/03/2016                 Ext                    EXT                   NA                     None                             NA                                                       36 (22), 54 (22)                                                               No GOSH contact; referred sample
  78^f^        BU      IPP             18/03/2016                      19/03/2016                 IP                     POA                   NA                     Y                                10 days                                                  36 (25), 54 (25)                                                               OPD 21/12/2015--15/01/2016 OPD 3/3/16 and 8/3/3016
  65           EXT     External        None                            03/03/2016                 Ext                    EXT                   NA                     None                             NA                                                       51 (24), 36 (30), 54 (30)                                                      No GOSH contact; referred sample

Abbreviations: ENT, ear nose throat; EXT, external sample referred for testing; GOSH, Great Ormond Street Hospital; Haem/Onc, hamatology/oncology; HAOPD, haematology/oncology outpatient department; HCAI, healthcare--acquired infection; ICU, intensive care unit; IP, inpatient; IPP, private patient; NA, not applicable; OP, outpatient; OPD, outpatient department; POA, positive on arrival; POPD, positive in outpatient department; Resp, respiratory; Rheum, rheumatology inpatient.

^a^Cluster 1 known outbreak.

^b^Cluster 2 and cases putatively linked to Cluster 2.

^c^Private patient, potentially sharing facilities and living accommodation.

^d^Attended OPD within 4 days of each other.

^e^Attended by the surgical team.

^f^Other putatively linked cases.

^g^Unlinked haemato-oncology cases.

The amounts of sequence data and read depths for 80 samples, obtained from 38 patients, are shown in [Table 2](#T2){ref-type="table"}. Genome coverage and read depth correlated well with the inverse of the original diagnostic real-time polymerase chain reaction cycle threshold values (rtPCR) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). We successfully sequenced 65 samples, with a mean read depth \>100X. The cut-off for generating whole genomes was cycle threshold 37 (approximately equivalent to 1000 gc/ml \[genome copies/millilitre\] of the original aspirate; [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). All samples were of the H1N1 genetic subtype 6B.1 and were phylogenetically distinct from the H1N1 vaccine strain used in the seasonal vaccine formulation ([Figure 1A](#F1){ref-type="fig"}). An analysis of the 65 samples, from 36 patients, revealed near identical sequences (3 or fewer differences) at the consensus level between samples taken from the same patient. Phylogenetic analyses of these 65 genome sequences and of 24 other influenza A sequences circulating during the same season identified 2 monophyletic outbreak clusters, with high bootstrap values, occurring in the hospital ([Figure 1A](#F1){ref-type="fig"}). Based on WGS, Cluster 1 was comprised of Patients 25, 26, and 27, and Cluster 2 contained Patients 53 and 54. Patients in Cluster 1 were all on the same ward at the time they became symptomatic, and this cluster had been previously identified by standard IPC procedures ([Table 1](#T1){ref-type="table"}). Cluster 2 was comprised of 2 patients, and this cluster had not previously been identified by IPC, as Patient 53 was initially noted to have been admitted with an acute infection from home. In addition, there was no phylogenetic evidence found for direct transmission between Patients 27 and 35 or between the 11 patients on the haematology/oncology wards. A phylogenetic analysis of HA/NA sequences alone generated a poorly supported tree, which identified both Clusters 1 and 2, but with low bootstrap values. Moreover, the tree failed to separate the sequences within these clusters from other closely related strains detected in the hospital ([Figure 1B](#F1){ref-type="fig"}). The HA/NA tree of Cluster 1 included Patient 35, who had been readmitted 48 hours after discharge by the same medical team caring for Patients 25 and 26, albeit on a different ward, but who was not directly linked. By WGS, the virus isolated from Patient 35 was separated from Cluster 1 by an unrelated sequence. By HA/NA phylogenetic analysis, Cluster 2 included not only Patients 53 and 54, but also Patients 45, 49, and 62. In contrast, WGS identified only Patients 53 and 54 as part of a monophyletic cluster.

###### 

Number of Clinical Samples Sequenced Successfully at Varying Genome Coverage and Depth of Coverage

                                           Number of Genomes Obtained
  ---------------------------------------- ----------------------------
  50% genome coverage at 1X mean depth     77
  90% genome coverage at 1X mean depth     73
  90% genome coverage at 100X mean depth   65

![Maximum likelihood trees for (*A*) whole-genome and (*B*) HA/NA concatenated genes. The strains sequenced in this study are color-coded by individual patients. Bootstrap support \>70% at nodes is highlighted using a black circle. The vaccine strain used in the formulation is highlighted in the box. Abbreviations: HA, haemagglutinin; NA, neuraminidase.](ciz020f0001){#F1}

To quantify further the differences between putative clusters of viruses and other viruses circulating during the same seasonal influenza epidemic, we calculated the pairwise genetic differences at the whole-genome level between strains circulating within the hospital and throughout Europe during the same season. For completeness, we compared the pairwise genetic differences for whole genomes with those obtained for concatenated HA/NA gene segments. The concatenated HA/NA genes, although among the most variable parts of the genome, revealed little differences in pairwise distances between epidemiologically unrelated strains co-circulating in the hospital during the same season: as shown in [Figure 2B](#F2){ref-type="fig"}, blue (within-patient variation, calculated using longitudinal samples), red (strains from an IPC-confirmed outbreak cluster), green (epidemiologically unlinked GOSH strains), and purple (influenza database) pairwise distances overlap with each other. In contrast, at the whole-genome level, within-patient pairwise distances, calculated from samples collected longitudinally, were less than 3 across the entire genome, over periods ranging from 3 to 34 days (shown in blue in [Figure 2A](#F2){ref-type="fig"}). The same pairwise variation was observed for viruses clustering as part of the confirmed outbreak in Cluster 1 (shown in red in [Figure 2A](#F2){ref-type="fig"}). The 2 strains in Cluster 2 differed by 1 substitution (shown in green in [Figure 2A](#F2){ref-type="fig"}). In [Figure 3](#F3){ref-type="fig"}, we show the genome locations of variable sites, occurring within sequences taken from an individual or between sequences forming a known transmission cluster (red) and variable sites that separate epidemiologically unrelated genomes (green). The wide distribution across the genome and the intermingling of these 2 groups suggests that it is not possible to sequence any sub-genomic regions to distinguish within and between host variations.

![Pairwise SNV between strains in the study. The blue bars highlight variations within an individual patient; the red bars highlight variations between confirmed outbreak sequences; the green bars highlight variations between epidemiologically unrelated sequences within the hospital; and the purple bars highlight variations between strains circulating in Europe in the same season. Whole-genome SNV (*A*) and (*B*) HA/NA concatenated SNV. Abbreviations: HA, haemagglutinin; NA, neuraminidase; SNV, single nucleotide variations.](ciz020f0002){#F2}

![Variable sites highlighted across the genome between related (red) and unrelated (green) influenza A strains. The different segments and their respective boundaries are shown on top. Abbreviations: HA, haemagglutinin; MA, matrix protein; NA, neuraminidase; NP, nucleoprotein; NS, nonstructural protein; PA, PB1, PB2, polymerase protein.](ciz020f0003){#F3}

The remaining GOSH strains, for which no direct epidemiological link could be found, fell into 4 normally distributed groups, labelled 1--4 (green in [Figure 2A](#F2){ref-type="fig"}). In 3 of these groups ([Table 1](#T1){ref-type="table"}), 12 or more pairwise differences were intermingled, with unrelated sequences obtained from the influenza database (purple in [Figure 2A](#F2){ref-type="fig"}). In contrast, members of the group with 6--11 pairwise changes were, with 1 exception, long-standing GOSH patients ([Table 1](#T1){ref-type="table"}). This group contained Patients 45 and 49, whose viral sequences, although distinct by WGS, clustered monophyletically with outbreak Cluster 2 (Patients 53 and 54) by HA/NA sequencing and also with Patients 40, 36, 37, 38, 45, 49, 70, and 81 ([Table 1](#T1){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}). [Figure 4A](#F4){ref-type="fig"} shows a timeline of when each patient within this group was sampled for the first time and the relationships between patients' influenza sequences. From this, it seems that Patients 38 and 40 were potentially linked to each other, but not to the others. Both had visited GOSH as outpatients within a week of each other, but otherwise had no identified link ([Table 1](#T1){ref-type="table"}). Patients 36, 37, 45, 49, 70, and 81 all appeared to have potential links to outbreak Cluster 2 (Patients 53 and 54). On further analysis ([Table 1](#T1){ref-type="table"} and [Figure 4B](#F4){ref-type="fig"}), we found evidence for 3 putative transmission chains. Patients 53 and 54 presented on the same day on different wards, but had no direct contact. It is, therefore, likely that they were infected from a common source. Since Patients 53, 36, and 37 had all attended the outpatient department within 3 days of each other, all 3 could have been infected by this source. While Patient 53 became infected within 48 hours of attending as an outpatient, Patients 36 and 37 did not present until several days (nearly 2 weeks) later, suggesting that infection may first have occurred in a family member. Patients 54, 49, and 81 all acquired influenza whilst inpatients on the surgical wards. It is possible, therefore, that the staff member who infected Patient 53 also worked on the surgical wards. Thereafter, spread from this staff member or from Patient 54 to staff or families on the surgical wards may have resulted indirectly in transmission to Patients 49 and 81. Of interest, Patients 53, 54, and 49 were all private patients, who were particularly likely to have been cared for by the same staff. No link could be found between Patients 45 or 70 and other patients in the putative transmission chain. Patient 45 was an externally referred sample from a patient known to GOSH. Although there was no record that this patient had visited the hospital recently, it is possible that he/she had an unrecorded ward or outpatient visit. Patient 70 was not known to GOSH and presented with community-acquired influenza.

![*A*, Table with dates of sampling for patients indirectly linked to cluster 2. *B*, Popart analysis of putative transmission chain of patients using a median joining network. Nodes with no labels are inferred nodes. The notches on each link between 2 nodes represent the number of changes between the 2 nodes at the whole-genome level.](ciz020f0004){#F4}

Patient 62, whose HA/NA sequence, but not the WGS, clustered with outbreak 2, had pairwise distances of ≥12 ([Table 1](#T1){ref-type="table"}). This child had briefly been an inpatient on the same ward as Patient 54 when the latter first became unwell, but had not had contact with GOSH since then and did not present until 6 weeks later. Similarly, while the HA/NA sequence from Patient 35 clustered with Patients 25, 26, and 27 (outbreak 1) and he/she was cared for by the same team, he/she had pairwise distances to other GOSH sequences of ≥13.

DISCUSSION {#s3}
==========

Our data suggest that HA and NA sequencing alone do not adequately discriminate directly transmitted strains from those that are co-circulating in the same location. A previous study, which concluded that HA and NA sequencing was adequate, differed from ours in that it used sequencing to confirm well-founded links, only sequencing viruses from subjects suspected to be part of 2 outbreaks \[[@CIT0014]\]. While this approach effectively distinguished the 2 outbreaks from each other, our study differed, in that we aimed to uncover previously unsuspected transmissions. Our approach revealed strains with identical HA and NA genes circulating in the same hospital population, as part of the same epidemic. In contrast, a phylogenetic analysis of WGS supported the direct transmission between Patients 25, 26, and 27, but excluded direct transmission to Patient 35, who had, by standard IPC methods, been tentatively linked to the outbreak. The closeness may, however, represent indirect transmission via other patients, relatives, or staff.

Applying standard influenza mutation rates of 0.09 mutations/genome/day \[[@CIT0022]\] to the samples collected longitudinally from the same individuals suggests that 3.18 substitutions would have been expected over the period of 34 days during which samples were collected. This figure fits well with the 0--3 substitutions identified in this group. WGS demonstrated that the epidemiologically supported transmissions in Cluster 1 differed by single nucleotide polymorphism (SNP) numbers similar to those seen from within-patient, longitudinally collected samples (ie, 1--3 SNPs). Phylogenetic and pairwise analyses also supported the second cluster, as directly linked cases ([Figure 2A](#F2){ref-type="fig"}). A retrospective analysis confirmed Patient 54, although presenting on the same day as Patient 53, was influenza positive on admission and was admitted to a different ward. Patients 53 and 54 had, therefore, not been considered linked by IPC methods. However, further investigation showed that Patient 54 had attended an outpatient unit run by the same medical team 2 days prior to their acute infection, raising the possibility that Patients 53 and 54 were infected by a common source. The need for WGS is further supported by our failure to identify clusters of variable sites that would enable more limited sequencing of subgenomic fragments to replace WGS ([Figure 3](#F3){ref-type="fig"}).

The phylogenetic data for the haemato-oncology patients among whom IPC investigations had suspected cryptogenic nosocomial transmission, indicated no evidence of transmission, and this was supported by the pairwise genetic distances between them. This confirms that no breakdown in IPC had occurred in this unit. We observed a population of viruses circulating among GOSH patients ([Figure 2A](#F2){ref-type="fig"}), which had pairwise genetic distances that were closer than those seen for any database viruses (6--11 versus \> 13 SNPs; [Figure 2A](#F2){ref-type="fig"}). Although no direct links between the patients could be found, an examination of the case histories showed that inpatient or outpatient care by the same medical team during the preceding weeks linked 8/10 of these patients. The possibility that Patient 45, for whom no link to other patients could be found, but who was a long-term GOSH patient, had had an undocumented outpatient visit remains unproven. Our data suggests transmission by unsampled, intermediate sources that led to Patients 53 and 54 becoming infected. The pattern of transmissions, occurring over a period of time, suggests that the original source may also have infected other staff or family members and led, eventually, to the infection of Patients 36 and 37. There were 3 patients, Patients 54, 49, and 81, who acquired their infections in the hospital, resulting in prolonged stays; Patient 36, who may have acquired the infection indirectly through outpatient attendance, required extra corporeal membrane oxygenation. Thus, the failure to interrupt this cryptic transmission proved costly, both medically and financially.

The use of pathogen genomic data to confirm and uncover putative transmission links between patients has the potential to be a powerful tool to aid traditional IPC approaches. We have shown that that the sensitivity and specificity of information provided by whole influenza genomes for the identification of true nosocomial clusters is greater than from sequencing HA and NA alone. Equally as important, we have shown that phylogenetic and pairwise distance analyses of WGS were able to uncover probable cryptogenic nosocomial influenza transmission in 1 unit, while excluding a suspected breakdown of IPC in the haemato-oncology unit. As turnaround times and per sample costs further decline, next-generation sequencing has the potential for routine use in clinical settings \[[@CIT0018]\]. As hybridization times reduce (now 1 hour), it will be possible to generate sequencing material faster. In addition, newer, third-generation sequencing technologies, such as the MinION from Oxford Nanopore \[[@CIT0023]\], have the potential for even faster turnaround times and are currently being tested for efficacy in real-time genotyping in a hospital setting. Our own experience of high-throughput, targeted enrichment methods has proven WGS of influenza to be sensitive, generating whole genomes from 1000 copies/ml, and fast, with turnaround times of 3--4 days and a cost of about £100/sample. While the infrastructure costs for high-throughput WGS include the purchase of robotics, low numbers of samples can be processed by hand. Here, we show the effectiveness of WGS and pairwise genetic analyses to identify direct transmissions that are not detected by standard IPC methods. While intensive sampling of staff and relatives would also be valuable, the data from whole genomes may, ultimately, render this unnecessary for uncovering linked infections. Notwithstanding, more data from staff and relatives could be useful for supporting campaigns to improve the uptake of the influenza vaccine among immunocompromised patients, their families, and the staff caring for them. As genomic data becomes linked to records of patient and staff movement, identifying accurately and in real time where breakdowns in IPC are occurring can become reality, thus allowing focused intervention to where it will have most impact. Such measures are likely to improve patient health and prove cost saving.

Supplementary Data {#s4}
==================

Supplementary materials are available at *Clinical Infectious Diseases online*. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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